Nipro Diagnostics, Inc. and NeuroMetrix, Inc. NURO today announced their collaboration to evaluate opportunities for NC-stat | DPNCheck in retail medical clinics. NC-stat DPNCheck is a rapid, quantitative, point-of-care test for the evaluation of systemic neuropathies such as diabetic peripheral neuropathy.
DPN affects more than half of people with diabetes and may lead to foot ulcers and limb amputation, as well as pain and an overall reduction in quality of life. Nipro and NeuroMetrix believe that this test may address the unmet medical need for better and cost-effective approaches to detecting and monitoring DPN.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in